Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.64 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.61 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.61 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894796 | 0.95 | PARP1 (0.64) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL1708875 | 0.90 | PARP1 (0.55) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL19828394 | 0.87 | PARP1 (0.56) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL3087859 | 0.87 | PARP1 (0.56) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL14192803 | 0.87 | PARP1 (0.56) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL23360890 | 0.86 | PARP1 (0.55) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL29826907 | 0.86 | PARP1 (0.55) | PARP1PARP10CA1CA2PARP2 | |
| Hydrochloric Acid SCHEMBL28611561 | 0.86 | PARP1 (0.55) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL1362735 | 0.86 | PARP1 (0.55) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL25432683 | 0.86 | PARP1 (0.55) | PARP1PARP10CA1CA2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119615412-A | Preparation method of flame-retardant fiber for fabric | 新疆诺纳纺织科技有限公司 | 2025-03-14 | — | — | CN | claimed |
| WO-2025065102-A1 | PHENYLTHIONE-2,3-DIHYDRO-1H-PYRROLIZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS H2S-RELEASING KETOROLAC ANALOGUES | ANTIBE THERAPEUTICS INC. (CA) | 2025-04-03 | — | — | WO | disclosed |
| CN-119615412-A | Preparation method of flame-retardant fiber for fabric | 新疆诺纳纺织科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-1379525-B1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMA INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1679313-A2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | PARP1 4043/4885PARP10 2983/4885CA1 972/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | PARP1 4043/4885PARP10 2983/4885CA1 972/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | PARP1 4043/4885PARP10 2983/4885CA1 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.